Open Access
Volume 7, Number 2, June 2017
Article Number 12
Number of page(s) 12
Published online 14 June 2017
  1. Yuan CH, Horng CT, Lee CF, Chiang NN, Tsai FJ, Lu CC, et al. Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/ STAT3 pathway and suppressing multidrug resistance 1 signaling. Environ Toxicol. 2017; 32: 845–855. [CrossRef] [PubMed] [Google Scholar]
  2. Chuang SL, Su WW, Chen SL, Yen AM, Wang CP, Fann JC, et al. Population-based screening program for reducing oral cancer mortality in 2, 334, 299 Taiwanese cigarette smokers and/or betel quid chewers. Cancer. 2017; 123: 1597–1609. [CrossRef] [PubMed] [Google Scholar]
  3. Tsai KY, Su CC, Chiang CT, Tseng YT, Lian IB. Environmental heavy metal as a potential risk factor for the progression of oral potentially malignant disorders in central Taiwan. Cancer Epidemiol. 2017; 47: 118–124. [CrossRef] [PubMed] [Google Scholar]
  4. Chou CH, Chou YE, Chuang CY, Yang SF, Lin CW. Combined effect of genetic polymorphisms of AURKA and environmental factors on oral cancer development in Taiwan. PLoS One. 2017; 12: e0171583. [PubMed] [Google Scholar]
  5. Chan CY, Lien CH, Lee MF, Huang CY. Quercetin suppresses cellular migration and invasion in human head and neck squamous cell carcinoma (HNSCC). Biomedicine (Taipei). 2016; 6: 15. [Google Scholar]
  6. Huang YP, Chang NW. PPARalpha modulates gene expression profiles of mitochondrial energy metabolism in oral tumorigenesis. Biomedicine (Taipei). 2016; 6: 3. [CrossRef] [PubMed] [Google Scholar]
  7. Butler C, Lee YA, Li S, Li Q, Chen CJ, Hsu WL, et al. Diet and the risk of head-and-neck cancer among never-smokers and smokers in a Chinese population. Cancer Epidemiol. 2017; 46: 20–26. [CrossRef] [PubMed] [Google Scholar]
  8. Wang WH, Hsuan KY, Chu LY, Lee CY, Tyan YC, Chen ZS, et al. Anticancer Effects of Salvia miltiorrhiza Alcohol Extract on Oral Squamous Carcinoma Cells. vid Based Complement Alternat Med. 2017; 2017: 5364010. [Google Scholar]
  9. Lien MY, Lin CW, Tsai HC, Chen YT, Tsai MH, Hua CH, et al. Impact of CCL4 gene polymorphisms and environmental factors on oral cancer development and clinical characteristics. Oncotarget. 2017. [Google Scholar]
  10. Tien AJ, Chien CY, Chen YH, Lin LC, Chien CT. Fruiting Bodies of Antrodia cinnamomea and Its Active Triterpenoid, Antcin K, Ameliorates N-Nitrosodiethylamine-Induced Hepatic Inflammation, Fibrosis and Carcinogenesis in Rats. Am J Chin Med. 2017; 45: 173–198. [CrossRef] [PubMed] [Google Scholar]
  11. Ragin C, Liu JC, Jones G, Shoyele O Sowunmi B Kennett R, et al. Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients. Carcinogenesis. 2016 [Google Scholar]
  12. Huang SF, Li HF, Liao CT, Wang HM, Chen IH, Chang JT, et al. Association of HPV infections with second primary tumors in early-staged oral cavity cancer. Oral Dis. 2012; 18: 809–815. [CrossRef] [PubMed] [Google Scholar]
  13. Suzuki R, Matsushima Y, Okudaira N, Sakagami H, Shirataki Y. Cytotoxic Components Against Human Oral Squamous Cell Carcinoma Isolated from Andrographis paniculata. Anticancer Res. 2016; 36: 5931–5935. [CrossRef] [PubMed] [Google Scholar]
  14. Kumar M, Nanavati R, Modi TG, Dobariya C. Oral cancer: Etiology and risk factors: A review. J Cancer Res Ther. 2016; 12: 45863. [Google Scholar]
  15. Schmaltz H, Borel C, Ciftci S, Takeda-Raguin C, Debry C, Schultz P, et al. Induction chemotherapy before surgery for unresectable head and neck cancer. B-ENT. 2016; 12: 29–32. [PubMed] [Google Scholar]
  16. Noronha V, Patil V, Joshi A, Muddu V, Bhattacharjee A, Juvekar S, et al. Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?. Indian J Cancer. 2015; 52: 70–73. [CrossRef] [PubMed] [Google Scholar]
  17. Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, et al. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol. 2016; 53: 54–59. [CrossRef] [PubMed] [Google Scholar]
  18. Chang CH, Lee CY, Lu CC, Tsai FJ, Hsu YM, Tsao JW, et al. Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling. Int J Oncol. 2017; 50: 873–882. [CrossRef] [PubMed] [Google Scholar]
  19. Ding L, Ren J, Zhang D, Li Y, Huang X, Ji J, et al. The TLR3 Agonist Inhibit Drug efflux and Sequentially Consolidates Low-dose Cisplatin-based Chemoimmunotherapy while Reducing Side effects. Mol Cancer Ther. 2017. [Google Scholar]
  20. Chung JG, Yang JS, Huang LJ, Lee FY, Teng CM, Tsai SC, et al. Proteomic approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Proteomics. 2007; 7: 3305–3317. [PubMed] [Google Scholar]
  21. Lee FY, Lien JC, Huang LJ, Huang TM, Tsai SC, Teng CM, et al. Synthesis of 1-benzyl-3-(5’-hydroxymethyl-2’-furyl)indazole analogues as novel antiplatelet agents. J Med Chem. 2001; 44: 3746–3749. [CrossRef] [PubMed] [Google Scholar]
  22. Chun YS, Yeo EJ, Park JW. Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett. 2004; 207: 1–7. [CrossRef] [Google Scholar]
  23. Nakane M. Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application. Clin Chem Lab Med. 2003; 41: 865–870. [CrossRef] [PubMed] [Google Scholar]
  24. Tulis DA, Bohl Masters KS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ, et al. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun. 2002; 291: 1014–1021. [CrossRef] [Google Scholar]
  25. Yun S, Lee SH, Kang YH, Jeong M, Kim MJ, Kim MS, et al. YC-1 enhances natural killer cell differentiation from hematopoietic stem cells. Int Immunopharmacol. 2010; 10: 481–486. [CrossRef] [PubMed] [Google Scholar]
  26. Lu DY, Tang CH, Liou HC, Teng CM, Jeng KC, Kuo SC, et al. YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia. Br J Pharmacol. 2007; 151: 396–405. [PubMed] [Google Scholar]
  27. Hwang TL, Hung HW, Kao SH, Teng CM, Wu CC, Cheng SJ. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol Pharmacol. 2003; 64: 1419–1427. [CrossRef] [PubMed] [Google Scholar]
  28. Wu SN. Large-conductance Ca2 + -activated K + channels: physiological role and pharmacology. Curr Med Chem. 2003; 10: 64961. [Google Scholar]
  29. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood. 1994; 84: 4226–4233. [Google Scholar]
  30. Wang J, Li G, Wang Y, Tang S, Sun X, Feng X, et al. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1alpha/VEGF secretion axis. Oncotarget. 2015; 6: 44579–44592. [CrossRef] [PubMed] [Google Scholar]
  31. Na JI, Na JY, Choi WY, Lee MC, Park MS, Choi KH, et al. The HIF-1 inhibitor YC-1 decreases reactive astrocyte formation in a rodent ischemia model. Am J Transl Res. 2015; 7: 751–760. [PubMed] [Google Scholar]
  32. Chio CC, Lin JW, Cheng HA, Chiu WT, Wang YH, Wang JJ, et al. MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch Toxicol. 2013; 87: 459–468. [CrossRef] [PubMed] [Google Scholar]
  33. Chou CW, Wang CC, Wu CP, Lin YJ, Lee YC, Cheng YW, et al. Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro Oncol. 2012; 14: 1227–1238. [CrossRef] [PubMed] [Google Scholar]
  34. Xiao J, Jin C, Liu Z, Guo S, Zhang X, Zhou X, et al. The design, synthesis, and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents. Org Biomol Chem. 2015; 13: 7257–7264. [CrossRef] [PubMed] [Google Scholar]
  35. Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM. The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development. Int J Oncol. 2013; 42: 179–187. [CrossRef] [PubMed] [Google Scholar]
  36. Chen CJ, Hsu MH, Huang LJ, Yamori T, Chung JG, Lee FY, et al. Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem Pharmacol. 2008; 75: 360–368. [CrossRef] [PubMed] [Google Scholar]
  37. Lee JC, Chou LC, Lien JC, Wu JC, Huang CH, Chung CH, et al. CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo. Oncol Rep. 2013; 30: 1762–1772. [CrossRef] [PubMed] [Google Scholar]
  38. Lee SJ, Kim YJ, Lee CS, Bae J. Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines. Chem Biol Interact. 2009; 181: 185–192. [CrossRef] [PubMed] [Google Scholar]
  39. Flamigni F, Facchini A, Stanic I, Tantini B, Bonavita F, Stefanelli C. Control of survival of proliferating L1210 cells by soluble guany-late cyclase and p44/42 mitogen-activated protein kinase modulators. Biochem Pharmacol. 2001; 62: 319–328. [CrossRef] [PubMed] [Google Scholar]
  40. Wang SX, Pei ZZ, Wu XH, Li JK, Yang YJ. Effect of YC-1 on HIF-1 alpha and VEGF expression in human hepatocarcinoma cell lines. Zhonghua Gan Zang Bing Za Zhi. 2009; 17: 308–309. [PubMed] [Google Scholar]
  41. Li Y, Zhao X, Tang H, Zhong Z, Zhang L, Xu R, et al. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells. Urol Int. 2012; 88: 95–101. [CrossRef] [PubMed] [Google Scholar]
  42. Zhao Q, Du J, Gu H, Teng X, Zhang Q, Qin H, et al. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas. 2007; 34: 242–247. [PubMed] [Google Scholar]
  43. Feng Y, Zhu H, Ling T, Hao B, Zhang G, Shi R. Effects of YC-1 targeting hypoxia-inducible factor 1 alpha in oesophageal squamous carcinoma cell line Eca109 cells. Cell Biol Int. 2011; 35: 491–497. [CrossRef] [PubMed] [Google Scholar]
  44. Lee CS, Kwak SW, Kim YJ, Lee SA, Park ES, Myung SC, et al. Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways. Eur J Pharmacol. 2012; 683: 54–62. [CrossRef] [PubMed] [Google Scholar]
  45. Liang D, Yang M, Guo B, Yang L, Cao J, Zhang X. HIF-1alpha induced by beta-elemene protects human osteosarcoma cells from undergoing apoptosis. J Cancer Res Clin Oncol. 2012; 138: 186577. [CrossRef] [Google Scholar]
  46. Chai ZT, Kong J, Zhu XD, Zhang YY, Lu L, Zhou JM, et al. MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2alpha/Akt/HIF-1alpha pathway in hepatocellular carcinoma. PLoS One. 2013; 8: e77957. [PubMed] [Google Scholar]
  47. Hong B, Lui VW, Hui EP, Lu Y, Leung HS, Wong EY, et al. Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochem Pharmacol. 2010; 79: 842–852. [CrossRef] [PubMed] [Google Scholar]
  48. Tuttle TR, Takiar V, Kumar B, Kumar P, Ben-Jonathan N. Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells. Cancer Lett. 2017; 389: 33–40. [CrossRef] [Google Scholar]
  49. Chou LC, Huang LJ, Yang JS, Lee FY, Teng CM, Kuo SC. Synthesis of furopyrazole analogs of 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole (YC-1) as novel anti-leukemia agents. Bioorg Med Chem. 2007; 15: 1732–1740. [CrossRef] [PubMed] [Google Scholar]
  50. Wang SW, Pan SL, Guh JH, Chen HL, Huang DM, Chang YL, et al. YC-1 [3-(5’-Hydroxymethyl-2’-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0–G1 in human hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2005; 312: 917–925. [CrossRef] [PubMed] [Google Scholar]
  51. Pan SL, Guh JH, Peng CY, Wang SW, Chang YL, Cheng FC, et al. YC-1 [3-(5’-hydroxymethyl-2’-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharmacol Exp Ther. 2005; 314: 35–42. [CrossRef] [PubMed] [Google Scholar]
  52. Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, et al. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Mol Cancer. 2014; 13: 7. [CrossRef] [PubMed] [Google Scholar]
  53. Cheng Y, Li W, Liu Y, Cheng HC, Ma J, Qiu L. YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro and in vivo under normoxic condition. Chin J Cancer. 2012; 31: 248–256. [CrossRef] [PubMed] [Google Scholar]
  54. Wu SY, Pan SL, Chen TH, Liao CH, Huang DY, Guh JH, et al. YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway. Br J Pharmacol. 2008; 155: 505–513. [PubMed] [Google Scholar]
  55. Chang LC, Lin HY, Tsai MT, Chou RH, Lee FY, Teng CM, et al. YC-1 inhibits proliferation of breast cancer cells by down- regulating EZH2 expression via activation of c-Cbl and ERK. Br J Pharmacol. 2014; 171: 4010–4025. [CrossRef] [PubMed] [Google Scholar]
  56. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst. 2003; 95: 516–525. [CrossRef] [PubMed] [Google Scholar]
  57. Mullershausen F, Russwurm M, Friebe A, Koesling D. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41–2272. Circulation. 2004; 109: 1711–1713. [CrossRef] [PubMed] [Google Scholar]
  58. Wang H, Kohr MJ, Traynham CJ, Ziolo MT. Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2 + current in cardiac myocytes. J Mol Cell Cardiol. 2009; 47: 30414. [Google Scholar]
  59. Chu PW, Beart PM, Jones NM. Preconditioning protects against oxidative injury involving hypoxia-inducible factor-1 and vascular endothelial growth factor in cultured astrocytes. Eur J Pharmacol. 2010; 633: 24–32. [CrossRef] [PubMed] [Google Scholar]
  60. Yeo EJ, Chun YS, Park JW. New anticancer strategies targeting HIF-1. Biochem Pharmacol. 2004; 68: 1061–1069. [CrossRef] [PubMed] [Google Scholar]
  61. Ikezawa Y, Sakakibara-Konishi J, Mizugaki H, Oizumi S, Nishimura M. Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer. Int J Clin Oncol. 2017; 22: 59–69. [CrossRef] [PubMed] [Google Scholar]
  62. Wan J, Wu W, Huang Y, Ge W, Liu S. Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70/HIF-1alpha. Oncol Rep. 2016; 36: 659–668. [CrossRef] [PubMed] [Google Scholar]
  63. Zhao T, Zhu Y, Morinibu A, Kobayashi M, Shinomiya K, Itasaka S, et al. HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Sci Rep. 2014; 4: 3793. [CrossRef] [PubMed] [Google Scholar]
  64. Nurwidya F, Takahashi F, Kobayashi I, Murakami A, Kato M, Minakata K, et al. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer. Biochem Biophys Res Commun. 2014; 455: 332–338. [CrossRef] [Google Scholar]
  65. Hsia TC, Liu WH, Qiu WW, Luo J, Yin MC. Maslinic acid induces mitochondrial apoptosis and suppresses HIF-1alpha expression in A549 lung cancer cells under normoxic and hypoxic conditions. Molecules. 2014; 19: 19892–19906. [CrossRef] [PubMed] [Google Scholar]
  66. Kambayashi S, Igase M, Kobayashi K, Kimura A, Shimokawa Miyama T, Baba K, et al. Hypoxia inducible factor 1alpha expression and effects of its inhibitors in canine lymphoma. J Vet Med Sci. 2015; 77: 1405–1412. [CrossRef] [PubMed] [Google Scholar]
  67. Chen WL, Wang CC, Lin YJ, Wu CP, Hsieh CH. Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme. J Transl Med. 2015; 13: 389. [CrossRef] [PubMed] [Google Scholar]
  68. Xue M, Li X, Li Z, Chen W. Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1alpha-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumour Biol. 2014; 35: 6901–6912. [CrossRef] [PubMed] [Google Scholar]
  69. Ma W, Shi X, Lu S, Wu L, Wang Y. Hypoxia-induced overexpression of DEC1 is regulated by HIF-1alpha in hepatocellular carcinoma. Oncol Rep. 2013; 30: 2957–2962. [CrossRef] [PubMed] [Google Scholar]
  70. Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, et al. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res. 2014; 16: R53. [CrossRef] [PubMed] [Google Scholar]
  71. Lee CS, Kim YJ, Kim W, Myung SC. Guanylate cyclase activator YC-1 enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells via activation of apoptosis-related proteins. Basic Clin Pharmacol Toxicol. 2011; 109: 283–291. [CrossRef] [PubMed] [Google Scholar]
  72. Dai Y, Bae K, Siemann DW. Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys. 2011; 81: 521–528. [CrossRef] [PubMed] [Google Scholar]
  73. Wang L, Zhou W, Gou S, Wang T, Liu T, Wang C. Insulin promotes proliferative vitality and invasive capability of pancreatic cancer cells via hypoxia-inducible factor 1alpha pathway. J Hua-zhong Univ Sci Technolog Med Sci. 2010; 30: 349–353. [CrossRef] [Google Scholar]
  74. Cho IR, Koh SS, Min HJ, Park EH, Ratakorn S, Jhun BH, et al. Down-regulation of HIF-1alpha by oncolytic reovirus infection independently of VHL and p53. Cancer Gene Ther. 2010; 17: 36572. [Google Scholar]
  75. Aubert S, Fauquette V, Hemon B, Lepoivre R, Briez N, Bernard D, et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 2009; 69: 5707–5715. [CrossRef] [Google Scholar]
  76. Deguchi A, Xing SW, Shureiqi I, Yang P, Newman RA, Lippman SM, et al. Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. Cancer Res. 2005; 65: 8442–8447. [CrossRef] [Google Scholar]
  77. Liu L, Li H, Underwood T, Lloyd M, David M, Sperl G, et al. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther. 2001; 299: 583–592. [PubMed] [Google Scholar]
  78. Wang F, Chen BA, Cheng J, Xu WL, Wang XM, Ding JH, et al. Effects of hypoxia-inducible factor inhibitor on expression of HIF- 1alpha and VEGF and induction of apoptosis in leukemic cell lines. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010; 18: 74–78. [PubMed] [Google Scholar]
  79. Hsu HK, Juan SH, Ho PY, Liang YC, Lin CH, Teng CM, et al. YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem Pharmacol. 2003; 66: 263–271. [CrossRef] [PubMed] [Google Scholar]
  80. Chiang WC, Teng CM, Lin SL, Chen YM, Tsai TJ, Hsieh BS. YC-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. Eur J Pharmacol. 2005; 517: 1–10. [CrossRef] [PubMed] [Google Scholar]
  81. Yeo EJ, Ryu JH, Chun YS, Cho YS, Jang IJ, Cho H, et al. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res. 2006; 66: 6345–6352. [CrossRef] [Google Scholar]
  82. Hung CC, Liou HH. YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs. 2011; 29: 1337–1346. [CrossRef] [PubMed] [Google Scholar]
  83. Zhou Q, Liu H, Sun Q, Zhang L, Lin H, Yuan G, et al. Adenosine monophosphate-activated protein kinase/mammalian target of rapamycin-dependent autophagy protects human dental pulp cells against hypoxia. J Endod. 2013; 39: 768–773. [CrossRef] [Google Scholar]
  84. Tung JN, Cheng YW, Hsu CH, Liu TZ, Hsieh PY, Ting LL, et al. Normoxically overexpressed hypoxia inducible factor 1-alpha is involved in arsenic trioxide resistance acquisition in hepatocellular carcinoma. Ann Surg Oncol. 2011; 18: 1492–1500. [CrossRef] [PubMed] [Google Scholar]
  85. Hsieh MT, Chen HP, Lu CC, Chiang JH, Wu TS, Kuo DH, et al. The novel pterostilbene derivative ANK-199 induces autophagic cell death through regulating PI3 kinase class III/beclin 1/Atgrelated proteins in cisplatinresistant CAR human oral cancer cells. Int J Oncol. 2014; 45: 782–794. [CrossRef] [PubMed] [Google Scholar]
  86. Chang PY, Peng SF, Lee CY, Lu CC, Tsai SC, Shieh TM, et al. Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. Int J Oncol. 2013; 43: 1141–1150. [CrossRef] [PubMed] [Google Scholar]
  87. Yang JS, Chen GW, Hsia TC, Ho HC, Ho CC, Lin MW, et al. Di-allyl disulfide induces apoptosis in human colon cancer cell line (COLO 205) through the induction of reactive oxygen species, endoplasmic reticulum stress, caspases casade and mitochondrial-dependent pathways. Food Chem Toxicol. 2009; 47: 171–179. [CrossRef] [PubMed] [Google Scholar]
  88. Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, Wu SH, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem. 2010; 58: 2935–2942. [CrossRef] [PubMed] [Google Scholar]
  89. Huang WW, Chiu YJ, Fan MJ, Lu HF, Yeh HF, Li KH, et al. Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondria-dependent pathway in human osteosarcoma U-2 OS cells. Mol Nutr Food Res. 2010; 54: 1585–1595. [CrossRef] [PubMed] [Google Scholar]
  90. Chang WM, Lin YF, Su CY, Peng HY, Chang YC, Hsiao JR, et al. Parathyroid Hormone-Like Hormone is a Poor Prognosis Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2 Regulation. Sci Rep. 2017; 7: 41131. [CrossRef] [PubMed] [Google Scholar]
  91. Chiu YJ, Hour MJ, Lu CC, Chung JG, Kuo SC, Huang WW, et al. Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway. J Orthop Res. 2011; 29: 1448–1456. [CrossRef] [PubMed] [Google Scholar]
  92. Yang JS, Hour MJ, Kuo SC, Huang LJ, Lee MR. Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38. Anticancer Res. 2004; 24: 1769–1778. [PubMed] [Google Scholar]
  93. Lin CF, Yang JS, Lin C, Tsai FJ, Lu CC, Lee MR. CCY-1a–E2 induces G2/M phase arrest and apoptotic cell death in HL-60 leukemia cells through cyclin-dependent kinase 1 signaling and the mitochondria-dependent caspase pathway. Oncol Rep. 2016; 36: 1633–1639. [CrossRef] [PubMed] [Google Scholar]
  94. Lai KC, Lu CC, Tang YJ, Chiang JH, Kuo DH, Chen FA, et al. Allyl isothiocyanate inhibits cell metastasis through suppression of the MAPK pathways in epidermal growth factorstimulated HT29 human colorectal adenocarcinoma cells. Oncol Rep. 2014; 31: 189–196. [CrossRef] [PubMed] [Google Scholar]
  95. Huang WW, Tsai SC, Peng SF, Lin MW, Chiang JH, Chiu YJ, et al. Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/ cyclin B in SK-HEP-1 human hepatic cancer cells. Int J Oncol. 2013; 42: 2069–2077. [CrossRef] [PubMed] [Google Scholar]
  96. Chen YF, Yang JS, Chang WS, Tsai SC, Peng SF, Zhou YR. Houttuynia cordata Thunb extract modulates G0/G1 arrest and Fas/CD95- mediated death receptor apoptotic cell death in human lung cancer A549 cells. J Biomed Sci. 2013; 20: 18. [CrossRef] [PubMed] [Google Scholar]
  97. Liu CY, Yang JS, Huang SM, Chiang JH, Chen MH, Huang LJ, et al. Smh-3 induces G(2)/M arrest and apoptosis through calcium-mediated endoplasmic reticulum stress and mitochondrial signaling in human hepatocellular carcinoma Hep3B cells. Oncol Rep. 2013; 29: 751–762. [CrossRef] [PubMed] [Google Scholar]
  98. Huang SH, Wu LW, Huang AC, Yu CC, Lien JC, Huang YP, et al. Benzyl isothiocyanate (BITC) induces G2/M phase arrest and apoptosis in human melanoma A375.S2 cells through reactive oxygen species (ROS) and both mitochondria-dependent and death receptor-mediated multiple signaling pathways. J Agric Food Chem. 2012; 60: 665–675. [CrossRef] [PubMed] [Google Scholar]
  99. Ma CY, Ji WT, Chueh FS, Yang JS, Chen PY, Yu CC, et al. Butein inhibits the migration and invasion of SK-HEP-1 human hepatocar- cinoma cells through suppressing the ERK, JNK, p38, and uPA signaling multiple pathways. J Agric Food Chem. 2011; 59: 9032–9038. [CrossRef] [PubMed] [Google Scholar]
  100. Chiang JH, Yang JS, Lu CC, Hour MJ, Chang SJ, Lee TH, et al. Newly synthesized quinazolinone HMJ-38 suppresses angiogeneticresponses and triggers human umbilical vein endothelial cell apoptosis through p53-modulated Fas/death receptor signaling. Toxicol Appl Pharmacol. 2013; 269: 150–162. [CrossRef] [PubMed] [Google Scholar]
  101. Lu CC, Yang JS, Chiang JH, Hour MJ, Lin KL, Lee TH, et al. Cell death caused by quinazolinone HMJ-38 challenge in oral carcinoma CAL 27 cells: dissections of endoplasmic reticulum stress, mitochondrial dysfunction and tumor xenografts. Biochim Biophys Acta. 2014; 1840: 2310–2320. [CrossRef] [PubMed] [Google Scholar]
  102. Lin C, Tsai SC, Tseng MT, Peng SF, Kuo SC, Lin MW, et al. AKT serine/threonine protein kinase modulates baicalin-triggered autophagy in human bladder cancer T24 cells. Int J Oncol. 2013; 42: 993–1000. [CrossRef] [PubMed] [Google Scholar]
  103. Tsai SC, Yang JS, Peng SF, Lu CC, Chiang JH, Chung JG, et al. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. Int J Oncol. 2012; 41: 1431–1442. [CrossRef] [PubMed] [Google Scholar]
  104. Lu CC, Yang JS, Chiang JH, Hour MJ, Lin KL, Lin JJ, et al. Novel quinazolinone MJ-29 triggers endoplasmic reticulum stress and intrinsic apoptosis in murine leukemia WEHI-3 cells and inhibits leukemic mice. PLoS One. 2012; 7: e36831. [PubMed] [Google Scholar]
  105. Peng SF, Lee CY, Hour MJ, Tsai SC, Kuo DH, Chen FA, et al. Curcumin-loaded nanoparticles enhance apoptotic cell death of U2OS human osteosarcoma cells through the Akt-Bad signaling pathway. Int J Oncol. 2014; 44: 238–246. [CrossRef] [PubMed] [Google Scholar]
  106. Tsai YF, Huang CW, Chiang JH, Tsai FJ, Hsu YM, Lu CC, et al. Gadolinium chloride elicits apoptosis in human osteosarcoma U-2 OS cells through extrinsic signaling, intrinsic pathway and endoplasmic reticulum stress. Oncol Rep. 2016; 36: 3421–3426. [CrossRef] [PubMed] [Google Scholar]
  107. Mason JM, Wei X, Fletcher GC, Kiarash R, Brokx R, Hodgson R, et al. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017; 114: 3127–3132. [CrossRef] [PubMed] [Google Scholar]
  108. Hour MJ, Lee KH, Chen TL, Lee KT, Zhao Y, Lee HZ. Molecular modelling, synthesis, cytotoxicity and anti-tumour mechanisms of 2-aryl-6-substituted quinazolinones as dual-targeted anti-cancer agents. Br J Pharmacol. 2013; 169: 1574–1586. [CrossRef] [PubMed] [Google Scholar]
  109. Sarkar J, Singh N, Meena S, Sinha S. Staurosporine induces apoptosis in human papillomavirus positive oral cancer cells at G2/M phase by disrupting mitochondrial membrane potential and modulation of cell cytoskeleton. Oral Oncol. 2009; 45: 974–979. [CrossRef] [PubMed] [Google Scholar]
  110. Carlson RO. New tubulin targeting agents currently in clinical development. Expert Opin Investig Drugs. 2008; 17: 707–722. [CrossRef] [PubMed] [Google Scholar]
  111. Tsui L, Fong TH, Wang IJ. The effect of 3-(5’-hydroxymethyl-2’- furyl)-1-benzylindazole (YC-1) on cell viability under hypoxia. Mol Vis. 2013; 19: 2260–2273. [PubMed] [Google Scholar]
  112. Huang YT, Pan SL, Guh JH, Chang YL, Lee FY, Kuo SC, et al. YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther. 2005; 4: 1628–1635. [CrossRef] [PubMed] [Google Scholar]
  113. Zhang Q, Bian H, Guo L, Zhu H. Pharmacologic preconditioning with berberine attenuating ischemia-induced apoptosis and promoting autophagy in neuron. Am J Transl Res. 2016; 8: 1197–1207. [PubMed] [Google Scholar]
  114. Yeh CH, Hsu SP, Yang CC, Chien CT, Wang NP. Hypoxic preconditioning reinforces HIF-alpha-dependent HSP70 signaling to reduce ischemic renal failure-induced renal tubular apoptosis and autophagy. Life Sci. 2010; 86: 115–123. [CrossRef] [PubMed] [Google Scholar]
  115. Wu J, Ke X, Wang W, Zhang H, Ma N, Fu W, et al. Aloe-emodin suppresses hypoxia-induced retinal angiogenesis via inhibition of HIF-1alpha/VEGF pathway. Int J Biol Sci. 2016; 12: 1363–1371. [CrossRef] [PubMed] [Google Scholar]
  116. Chang LH, Pan SL, Lai CY, Tsai AC, Teng CM. Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-alpha- induced TGF-alpha expression and MEK/VEGF-A-mediated an- giogenesis. Am J Pathol. 2013; 183: 566–575. [CrossRef] [PubMed] [Google Scholar]
  117. Liu YN, Pan SL, Peng CY, Guh JH, Huang DM, Chang YL, et al. YC-1 [3-(5’-hydroxymethyl-2’-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther. 2006; 316: 35–41. [CrossRef] [PubMed] [Google Scholar]
  118. Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett. 2007; 255: 107–116. [CrossRef] [Google Scholar]
  119. Kim HL, Yeo EJ, Chun YS, Park JW. A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. Int J Oncol. 2006; 29: 255–260. [PubMed] [Google Scholar]
  120. Lau CK, Yang ZF, Lam SP, Lam CT, Ngai P, Tam KH, et al. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther. 2007; 6: 1900–1907. [CrossRef] [PubMed] [Google Scholar]
  121. Birkinshaw RW, Czabotar PE. The BCL-2 family of proteins and mitochondrial outer membrane permeabilisation. Semin Cell Dev Biol. 2017. [Google Scholar]
  122. Shakeri R, Kheirollahi A, Davoodi J. Apaf-1: Regulation and function in cell death. Biochimie. 2017; 135: 111–125. [CrossRef] [PubMed] [Google Scholar]
  123. Li P, Zhou L, Zhao T, Liu X, Zhang P, Liu Y, et al. Caspase-9: structure, mechanisms and clinical application. Oncotarget. 2017; 8: 23996–24008. [PubMed] [Google Scholar]
  124. Maes ME, Schlamp CL, Nickells RW. BAX to basics: How the BCL2 gene family controls the death of retinal ganglion cells. Prog Retin Eye Res. 2017; 57: 1–25. [CrossRef] [PubMed] [Google Scholar]
  125. Ho TF, Chang CC. A promising “TRAIL” of tanshinones for cancer therapy. Biomedicine (Taipei). 2015; 5: 23. [CrossRef] [PubMed] [Google Scholar]
  126. Harma V, Schukov HP, Happonen A, Ahonen I, Virtanen J, Siitari H, et al. Quantification of dynamic morphological drug responses in 3D organotypic cell cultures by automated image analysis. PLoS One. 2014; 9: e96426. [PubMed] [Google Scholar]
  127. Single A, Beetham H, Telford BJ, Guilford P, Chen A. A Comparison of Real-Time and Endpoint Cell Viability Assays for Improved Synthetic Lethal Drug Validation. J Biomol Screen. 2015; 20: 1286–1293. [CrossRef] [PubMed] [Google Scholar]
  128. Bain JM, Louw J, Lewis LE, Okai B, Walls CA, Ballou ER, et al. Candida albicans hypha formation and mannan masking of beta-glucan inhibit macrophage phagosome maturation. MBio. 2014; 5: e01874. [PubMed] [Google Scholar]